Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures.
- Kanis JA Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, S10 2RX, Sheffield, UK. w.j.Pontefract@shef.ac.uk.
- Harvey NC MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.
- McCloskey E Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, S10 2RX, Sheffield, UK.
- Bruyère O World Health Organization Collaborating Center for the Public Health Aspects of Musculoskeletal Health and Aging, Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.
- Veronese N National Research Council, Neuroscience Institute, Aging Branch, Via Giustiniani, 2, 35128, Padova, Italy.
- Lorentzon M Mary McKillop Health Institute, Australian Catholic University, Melbourne, Australia.
- Cooper C MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.
- Rizzoli R Service of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
- Adib G Syrian National Osteoporosis Society, Damascus, Syria.
- Al-Daghri N Chair for Biomarkers of Chronic Diseases, Biochemistry Dept., College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia.
- Campusano C Clinica Universidad de los Andes and Faculty of Medicine, Universidad de los Andes, Santiago, Chile.
- Chandran M Osteoporosis and Bone Metabolism Unit, Department of Endocrinology, Singapore General Hospital, ACADEMIA, 20, College Road, Singapore, 169856, Singapore.
- Dawson-Hughes B Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA.
- Javaid K NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK.
- Jiwa F Chair of the Committee of Patients Societies at the International Osteoporosis Foundation, Osteoporosis Canada, Toronto, Canada.
- Johansson H Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, S10 2RX, Sheffield, UK.
- Lee JK Beacon International Specialist Centre, Petaling Jaya, Malaysia.
- Liu E Mary McKillop Health Institute, Australian Catholic University, Melbourne, Australia.
- Messina D IRO Medical Research Center, Buenos Aires and Rheumatology section, Cosme Argerich, Buenos Aires, Argentina.
- Mkinsi O Department of Rheumatology, Ibn Rochd University Hospital, Casablanca, Morocco.
- Pinto D Department of Physical Therapy, Marquette University, Milwaukee, WI, USA.
- Prieto-Alhambra D NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK.
- Saag K University of Alabama at Birmingham, Birmingham, AL, USA.
- Xia W Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Shuaifuyuan No. 1, Wangfujing, Dongcheng District, Beijing, 100730, China.
- Zakraoui L Service de Rhumatologie, University Tunis Manar and Hôpital Mongi-Slim, la Marsa, Tunisia.
- Reginster J- Chair for Biomarkers of Chronic Diseases, Biochemistry Dept., College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia.
- 2019-11-14
Published in:
- Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. - 2020
Anabolic agents
FRAX
Fracture risk assessment
Inhibitors of bone resorption
Treatment of osteoporosis
English
Guidance is provided in an international setting on the assessment and specific treatment of postmenopausal women at low, high and very high risk of fragility fractures.
INTRODUCTION
The International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published guidance for the diagnosis and management of osteoporosis in 2019. This manuscript seeks to apply this in an international setting, taking additional account of further categorisation of increased risk of fracture, which may inform choice of therapeutic approach.
METHODS
Clinical perspective and updated literature search.
RESULTS
The following areas are reviewed: categorisation of fracture risk and general pharmacological management of osteoporosis.
CONCLUSIONS
A platform is provided on which specific guidelines can be developed for national use to characterise fracture risk and direct interventions.
INTRODUCTION
The International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published guidance for the diagnosis and management of osteoporosis in 2019. This manuscript seeks to apply this in an international setting, taking additional account of further categorisation of increased risk of fracture, which may inform choice of therapeutic approach.
METHODS
Clinical perspective and updated literature search.
RESULTS
The following areas are reviewed: categorisation of fracture risk and general pharmacological management of osteoporosis.
CONCLUSIONS
A platform is provided on which specific guidelines can be developed for national use to characterise fracture risk and direct interventions.
- Language
-
- English
- Open access status
- hybrid
- Identifiers
-
- DOI 10.1007/s00198-019-05176-3
- PMID 31720707
- Persistent URL
- https://sonar.ch/global/documents/194347
Statistics
Document views: 49
File downloads:
- Full-text: 0